Retatrutide
Triple-action peptide with 24% average weight loss in trials.
Read the full profileHead-to-head reference
RetatrutideversusSemaglutide
The newest triple-agonist against the most established GLP-1 — a plain-English look at how retatrutide and semaglutide differ in action and dosing.
Profile dataSide-by-side fieldsReviewed July 13, 2026
01Short answer
Retatrutide and Semaglutide are different compounds.
This guide compares the same profile fields for both. It does not decide which is better, recommend either compound, or determine whether switching or combining them is appropriate.
02
Specimen cards
Meet the two profiles
Semaglutide
FDA-approved GLP-1 that produced 15% weight loss in trials.
Read the full profile03
Field notes
Compare them side by side
Profile fieldARetatrutideBSemaglutide
Overview
Retatrutide is a triple-action peptide that tells your body to eat less, burn more calories through glucagon, and improve blood sugar control, all in one molecule for powerful weight and metabolic effects.
Semaglutide is an FDA-approved GLP-1 receptor agonist that has transformed treatment of obesity and type 2 diabetes. It works by mimicking the hormone GLP-1 to reduce appetite, slow stomach emptying, and improve insulin sensitivit...
Safety
Grade C · Moderate Safety
Still in clinical trials. GI side effects are common but manageable.
Investigational drug, not yet approved. Titrate slowly to minimize side effects. Do not mix in the same syringe as other peptides. Inject GLP-1s on their own.
Grade B · Good Safety
FDA-approved with well-characterized side effects. GI issues are common but manageable.
Contraindicated in medullary thyroid cancer or MEN 2 syndrome. May cause pancreatitis. Do not mix in the same syringe as other peptides. Inject GLP-1s on their own.
Profile dosing context
Start at 0.5 mg weekly, titrate to 2.5-5 mg weekly
weekly
12 weeks on, 12 weeks off (per clinical trials)
Slow titration is key. Increase dose every 4 weeks to minimize GI effects
Injection: Start 0.25 mg weekly, titrate to 1-2.4 mg weekly. Oral: Start 3 mg daily, up to 14 mg daily
weekly
Ongoing as prescribed
Titrate slowly over months to minimize GI side effects; take oral on empty stomach
Requires titration
Yes
Yes
Occasional side effects
- Nausea
- Vomiting
- Diarrhea
- Injection site irritation
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Same fields. No invented certainty.
The comparison pulls from the live peptide profiles used across The Peptide App. Use it to spot differences in documented context, titration notes, and safety flags. Missing data remains missing rather than being inferred.
- Retatrutide
- Triple-action peptide with 24% average weight loss in trials.
- Semaglutide
- FDA-approved GLP-1 that produced 15% weight loss in trials.
Useful context, without a protocol.
What's the difference between Retatrutide and Semaglutide?
Retatrutide and Semaglutide are distinct compounds and can differ in mechanism, documented profile context, titration notes, evidence, and safety flags. The comparison table shows the same stored fields side by side and leaves unavailable information blank.
Is Retatrutide or Semaglutide better?
There is no universal answer, and this page does not rank or recommend either compound. A licensed professional can interpret the evidence, product status, and individual context; this page is only a structured research comparison.
Can you take Retatrutide and Semaglutide together?
Combining peptides can change dosing complexity and risk. This comparison is not medical advice, and it should not be used to start, stop, or combine protocols. A licensed professional is the right person to evaluate whether any combination is appropriate.
This comparison is for research and educational purposes. It does not diagnose, treat, prescribe, or replace guidance from a licensed professional. Always follow the instructions provided with your product.
From research to routine
Open the appTrack either protocol with less guesswork.
Keep dose timing, reminders, and protocol notes together in The Peptide App.